Abcam (LSE:ABC, Financial) is a web-based retailer of research antibodies. Like Oxford Instruments, a large portion of Abcam’s revenues depends on public funding for research. While public research funding trends seem to have stabilized, Abcam will be investing heavily to increase its portfolio of products and expand geographically. This will result in lower growth rates than the company has achieved historically. Given the recent sell-off in Abcam’s stock, its leading market position, and strong business model, we believe the market is presenting us with a buying opportunity.
From Wasatch International Growth (Trades, Portfolio) Fund's first quarter 2014 commentary.
